Lode-Star Mining Inc. (LSMG)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lode-Star Mining Inc. (LSMG) trades at $0.10 with AI Score 44/100 (Grade C). Lode-Star Mining Inc. is a basic materials company focused on developing drug candidates based on Epigallocatechin-gallate (EGCG). Market cap: $34.58M, Sector: Basic materials.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for LSMG: LSMG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LSMG against Basic Materials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LSMG: the 1 perspectives are evenly split.
How is this calculated? →Lode-Star Mining Inc. (LSMG) Materials & Commodity Exposure
Lode-Star Mining Inc., a subsidiary of Lode Star Gold Inc., is a basic materials company focused on the development of EGCG-based drug candidates, an antioxidant polyphenol with potential health benefits. Operating from Reno, Nevada, the company navigates the industrial materials sector with a focus on pharmaceutical applications.
What Is the Investment Thesis for LSMG?
Lode-Star Mining Inc. presents a speculative investment opportunity within the basic materials sector, specifically targeting pharmaceutical applications of EGCG. The company's focus on developing EGCG-based drug candidates could yield significant returns if successful, given the molecule's potential health benefits. However, the company's small market capitalization of $34.58M and negative P/E ratio of -311.74 indicate substantial risk. The high beta of 4.85 suggests extreme volatility relative to the market. Key value drivers include successful development and commercialization of EGCG-based drugs. Growth catalysts involve positive clinical trial results and potential partnerships with larger pharmaceutical companies. Risk factors include the uncertainty inherent in drug development, the company's limited financial resources, and the competitive landscape within the pharmaceutical industry.
Based on FMP financials and quantitative analysis
LSMG Key Highlights
- Market capitalization of $34.58M indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -311.74 reflects the company's current lack of profitability, typical for early-stage pharmaceutical development companies.
- Beta of 4.85 suggests the stock is significantly more volatile than the overall market.
- The company's focus on EGCG, an antioxidant polyphenol, aligns with growing consumer interest in natural health solutions.
- As a subsidiary of Lode Star Gold Inc., Lode-Star Mining benefits from the resources and expertise of its parent company.
Who Are LSMG's Competitors?
LSMG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANGVF Angus Gold Inc. | $0.59 | +0.00% | $35.72M | 44 |
| BBSRF Bluestone Resources Inc. | $0.22 | -0.59% | $33.59M | 44 |
| CMETF Power Nickel Inc. | $0.26 | -0.79% | $30.96M | 44 |
| CPRRF Allied Copper Corp. | $0.28 | +11.29% | $35.55M | 46 |
| GTAGF Golden Tag Resources Ltd. | $0.08 | -3.30% | $31.27M | 44 |
| GTMLF Green Technology Metals Limited | $0.01 | +0.00% | $8.28M | 64 |
| ABAT American Battery Technology Company | $2.81 | +1.81% | $295.15M | 64 |
| ARRRF Ardea Resources Limited | $0.30 | +10.00% | $65.26M | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LSMG's Key Strengths?
- Focus on EGCG, a molecule with potential health benefits.
- Subsidiary of Lode Star Gold Inc., providing access to resources.
- Potential for developing novel drug candidates.
- Located in Reno, Nevada, a business-friendly environment.
What Are LSMG's Weaknesses?
- Small market capitalization, indicating limited financial resources.
- Negative P/E ratio, reflecting current lack of profitability.
- High beta, suggesting significant stock volatility.
- Dependence on successful drug development and commercialization.
What Could Drive LSMG Stock Higher?
- Clinical trial results for EGCG-based drug candidates.
- Potential partnerships with pharmaceutical companies.
- Research and development of new EGCG formulations.
- Efforts to secure patents for proprietary technologies.
What Are the Key Risks for LSMG?
- Financial-distress signal — its Altman Z-Score of -16.07 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory hurdles associated with drug development.
- Competition from established pharmaceutical companies.
- Limited financial resources.
- High stock volatility due to OTC listing and small market cap.
What Are the Growth Opportunities for LSMG?
- Expansion into new therapeutic areas: Lode-Star Mining can explore the use of EGCG in treating a wider range of diseases and conditions. The market for antioxidant-based therapies is expanding, offering opportunities to develop new products targeting specific health needs. Success in this area depends on the company's ability to identify and validate new therapeutic applications for EGCG, potentially leading to increased revenue streams and market share.
- Partnerships with pharmaceutical companies: Collaborating with established pharmaceutical companies can provide Lode-Star Mining with access to funding, expertise, and distribution channels. Strategic alliances can accelerate the development and commercialization of EGCG-based drugs, increasing the likelihood of success and maximizing market penetration. This approach can mitigate the risks associated with drug development and provide a pathway to profitability.
- Securing patents for EGCG-based formulations: Obtaining patent protection for its proprietary EGCG formulations can provide Lode-Star Mining with a competitive advantage. Patents can prevent other companies from developing and selling similar products, allowing Lode-Star Mining to capture a larger share of the market. This strategy is crucial for protecting the company's intellectual property and ensuring long-term profitability.
- Clinical trial success: Positive results from clinical trials are essential for demonstrating the safety and efficacy of Lode-Star Mining's EGCG-based drug candidates. Successful clinical trials can attract investment, validate the company's technology, and pave the way for regulatory approval and commercialization. This is a critical milestone for the company and a key driver of future growth.
- Geographic expansion: Lode-Star Mining can expand its operations into new geographic markets, particularly in regions with a high prevalence of chronic diseases. Entering new markets can increase the company's revenue base and diversify its risk profile. This strategy requires careful planning and execution, but it can provide significant growth opportunities in the long term.
What Opportunities Does LSMG Have?
- Expansion into new therapeutic areas.
- Partnerships with pharmaceutical companies.
- Securing patents for EGCG-based formulations.
- Positive results from clinical trials.
What Threats Does LSMG Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles associated with drug development.
- Uncertainty inherent in drug development.
- Potential for clinical trial failures.
What Are LSMG's Competitive Advantages?
- Proprietary EGCG formulations.
- Patent protection for drug candidates.
- Clinical trial data demonstrating drug efficacy.
- Strategic partnerships with pharmaceutical companies.
What Does LSMG Do?
Lode-Star Mining Inc., based in Reno, Nevada, is a basic materials company dedicated to the development of drug candidates centered around the Epigallocatechin-gallate (EGCG) molecule. EGCG, an antioxidant polyphenol, is recognized for its potential health benefits, and Lode-Star Mining aims to harness these properties for pharmaceutical applications. As a subsidiary of Lode Star Gold Inc., Lode-Star Mining operates within the industrial materials sector, focusing specifically on the intersection of material science and pharmaceutical research. The company's activities involve researching, developing, and potentially commercializing EGCG-based drugs. The company is working to translate the health benefits of EGCG into viable pharmaceutical products. Lode-Star Mining's strategy involves identifying specific health conditions that could benefit from EGCG's properties and then developing targeted drug candidates to address those conditions. While specific details on their pipeline and clinical trial stages are not available, the company's focus remains on leveraging EGCG's antioxidant and other beneficial properties for therapeutic purposes.
What Products and Services Does LSMG Offer?
- Develop drug candidates based on Epigallocatechin-gallate (EGCG).
- Research the health benefits of EGCG.
- Formulate EGCG-based drugs for various health conditions.
- Conduct clinical trials to evaluate the safety and efficacy of their drugs.
- Seek regulatory approval for their drug candidates.
- Potentially commercialize and market EGCG-based drugs.
How Does LSMG Make Money?
- Develop and patent EGCG-based drug formulations.
- Conduct research and clinical trials to validate drug efficacy.
- Seek partnerships with pharmaceutical companies for funding and distribution.
- Potentially generate revenue through drug sales, licensing agreements, or acquisitions.
What Industry Does LSMG Operate In?
Lode-Star Mining Inc. operates within the industrial materials sector, focusing on the development of pharmaceutical products. The market for antioxidant-based therapeutics is growing, driven by increasing awareness of the health benefits of antioxidants and the rising prevalence of chronic diseases. The competitive landscape includes both established pharmaceutical companies and smaller biotech firms exploring novel therapeutic approaches. Lode-Star Mining's success depends on its ability to differentiate its EGCG-based drug candidates and navigate the regulatory hurdles associated with drug development.
Who Are LSMG's Key Customers?
- Pharmaceutical companies seeking novel drug candidates.
- Patients with health conditions that may benefit from EGCG.
- Healthcare providers who prescribe or recommend EGCG-based treatments.
- Research institutions interested in studying the health benefits of EGCG.
F-Score 3/9Financial Health
Lode-Star Mining Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.07 places it in the distress zone, a signal of elevated financial risk.
ROE 0%Key Financial Metrics
Return on equity for Lode-Star Mining Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Lode-Star Mining Inc. (LSMG) Valuation Context
Valued at $34.58M, LSMG is classified as a micro-cap stock. Relative to its peer group, LSMG's quantitative score of 44/100 is roughly in line with the peer average of 44/100.
LSMG Financials
Bull Case vs Bear Case
Bull Case
- Focus on EGCG, a molecule with potential health benefits.
- Subsidiary of Lode Star Gold Inc., providing access to resources.
- Potential for developing novel drug candidates.
- Located in Reno, Nevada, a business-friendly environment.
Bear Case
- Small market capitalization, indicating limited financial resources.
- Negative P/E ratio, reflecting current lack of profitability.
- High beta, suggesting significant stock volatility.
- Dependence on successful drug development and commercialization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
LSMG Latest News
No recent news available for LSMG.
LSMG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LSMG.
Price Targets
Wall Street price target analysis for LSMG.
LSMG MoonshotScore
What does this score mean?
The MoonshotScore rates LSMG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mark Walmesley
CEO
Information on Mark Walmesley's background is limited. Details regarding his career history, education, and previous roles are not available in the provided data. Therefore, a comprehensive biography cannot be constructed at this time. Further research would be required to provide a detailed overview of his professional experience and qualifications.
Track Record: Due to the limited information available regarding Mark Walmesley's background, it is not possible to assess his track record or identify key achievements and strategic decisions made under his leadership. Further research would be necessary to evaluate his performance and contributions to Lode-Star Mining Inc.
LSMG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lode-Star Mining Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is generally considered to be the most speculative and carries the highest risk for investors due to the potential for limited information and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to the OTC Other tier.
- Potential for pump-and-dump schemes.
- Higher risk of fraud or mismanagement.
- Limited liquidity and wider bid-ask spreads.
- Greater price volatility compared to exchange-listed stocks.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Research the background and experience of the company's management team.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Monitor the company's news and filings for any red flags.
- Subsidiary of Lode Star Gold Inc.
- Focus on developing EGCG-based drug candidates.
- Company is based in Reno, Nevada.
- Company has a CEO.
What Investors Ask About Lode-Star Mining Inc. (LSMG) — Basic Materials
What does Lode-Star Mining Inc. do?
Lode-Star Mining Inc. is a basic materials company focused on the development of drug candidates based on Epigallocatechin-gallate (EGCG), an antioxidant polyphenol. The company aims to harness the potential health benefits of EGCG for pharmaceutical applications. As a subsidiary of Lode Star Gold Inc., Lode-Star Mining operates within the industrial materials sector, specifically targeting the intersection of material science and pharmaceutical research. Their business model involves researching, developing, and potentially commercializing EGCG-based drugs.
What do analysts say about LSMG stock?
As of 2026-03-17, formal analyst ratings for Lode-Star Mining Inc. (LSMG) are unavailable, likely due to its small market capitalization and OTC listing. Given the company's negative P/E ratio of -311.74 and high beta of 4.85, potential investors should be aware of the speculative nature of this investment. The company's success hinges on the successful development and commercialization of its EGCG-based drug candidates, which carries inherent risks. Further independent research is essential before making any investment decisions.
What are the main risks for LSMG?
The main risks for Lode-Star Mining Inc. include the inherent uncertainties of drug development, such as clinical trial failures and regulatory hurdles. The company's limited financial resources, indicated by its small market capitalization of $34.58M, pose a significant risk. Competition from established pharmaceutical companies and the high volatility associated with OTC-listed stocks further contribute to the risk profile. Investors should carefully consider these factors before investing in LSMG.
What are the key factors to evaluate for LSMG?
Lode-Star Mining Inc. (LSMG) holds an AI score of 44/100 (low). Not financial advice.
How frequently does LSMG data refresh on this page?
LSMG prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LSMG's recent stock price performance?
Lode-Star Mining Inc. (LSMG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on EGCG, a molecule with potential health benefits. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LSMG overvalued or undervalued right now?
Valuing Lode-Star Mining Inc. (LSMG) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LSMG?
Before investing in Lode-Star Mining Inc. (LSMG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Lode-Star Mining Inc.
- OTC stocks are inherently riskier than exchange-listed stocks.
- AI analysis pending for LSMG.